Ruchin Kansal, Boehringer Ingelheim‘s head of business innovation for life sciences, digital health, and healthcare systems, said it would support the commercialization of Propeller Health‘s medication adherence tracking for its Respimat inhalers.
The move will give patients on Boehringer Ingelheim drugs for respiratory conditions the option to enroll with certain health systems to get free access to the connected inhalers embedded with Propeller Health sensors.
The sensor Propeller developed records the time and location of medication use and has a companion app to track inhaler use over time. The idea is to give doctors a window on their patients health between appointments. Equally important, it will show them how well the pharmaceutical’s medication is working (or not) and at least make it easier to engage in conversations in patients to figure out if a worsening condition is due to a medication, adherence or other issues.
In a phone interview with Kansal, he said the deal expands access to connected device and companion apps to 2,500 patients and is an expansion of its relationship with Propeller Health.
The deal comes about one year after the U.S. Food and Drug Administration cleared the use of BI’s inhaler with Propeller Health’s digital program. Propeller also works with GSK, which also secured FDA clearance for use of its dry powder inhaler with Propeller sensors last year.
Last month, drug delivery business Aptar Pharma inked a commercialization agreement with Propeller.
